LMP2 Antigen-specific TCR T cells

LMP2 Antigen-specific TCR T cells is a T cell receptor engineered T cell therapy that targets the Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2). This therapy involves genetically modifying T lymphocytes to express a T-cell receptor (TCR) specific for LMP2, which is expressed in EBV-associated cancers. Upon administration, these engineered T cells recognize and bind to LMP2-expressing cancer cells, promoting cell death and inhibiting tumor growth. The therapy is being developed primarily for recurrent and metastatic nasopharyngeal carcinoma with positive EBV infection.

Other names

LMP2-specific T-cell receptor-transduced autologous T lymphocytesLMP-2-specific T-cell receptor-transduced autologous T lymphocytesLMP 2-specific T-cell receptor-transduced autologous T lymphocytesLMP2-specific IL-12-secreting T cell receptor-transduced T lymphocytesLMP-2-specific IL-12-secreting T cell receptor-transduced T lymphocytesLMP 2-specific IL-12-secreting T cell receptor-transduced T lymphocytesLMP2 Antigen-specific High-affinity T Cell Receptor (TCR)-Transduced Autologous T-cell TherapyEBV TCR-T cells